Скачать или смотреть Alpha Cognition (ACOG) CEO Michael McFadden Pitch, Interview, Discussion, Deep Dive & Q&A

Presentation, Deep Dive & Q&A with
CEO Michael McFadden
Alpha Cognition Thu, Sep 19

Alpha Cognition is a clinical-stage, biopharmaceutical company dedicated to developing treatments for underserved neurodegenerative diseases, such as Alzheimer's dementia and amyotrophic lateral sclerosis (ALS). Alpha-1062 is a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with minimal gastrointestinal side effects and novel routes of administration. Alpha-1062's active metabolites are differentiated from donepezil and rivastigmine in that they may sensitize neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Alpha-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia and in a nasal spray formulation to treat traumatic brain injury.
https://www.alphacognition.com/

0:00:00 Opening & Disclaimers
0:00:31 Why
0:01:20 Pitch
0:04:50 Pipeline
0:10:50 Alpha 1062
0:40:38 Company Catalysts
0:41:40 Management


ACOG Stock